Advanced Accelerator Applications SA
LysaKare - Prescribing Information
LysaKare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
Most popular related searches
